<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01933282</url>
  </required_header>
  <id_info>
    <org_study_id>MESA-NKT2013</org_study_id>
    <nct_id>NCT01933282</nct_id>
  </id_info>
  <brief_title>MESA Treatment for NK/T Cell Lymphoma</brief_title>
  <acronym>MTN</acronym>
  <official_title>Phase II Study of MESA Chemotherapy in Patients With Natural Killer/T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Air Force Military Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Air Force Military Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study on the efficacy and safety of MESA chemotherapy for treating NK/T cell lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and&#xD;
      heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%~10%.&#xD;
      The frequency of ENKTL among NHL patients is significantly higher in Asia than in Western&#xD;
      countries. Despite radiotherapy and chemotherapy, the prognosis for ENKTL patients is poor,&#xD;
      with 5-year median survival time for primary nasal site was 5 years, for non-nasal extranodal&#xD;
      sites 6 months. ENKTL is so aggressive and has high mortality rate and till now there is no&#xD;
      standard therapy. In recent years SMILE chemotherapy has clinical efficacy and is one of&#xD;
      first line therapy for ENKTL. However it is apparent that this regimen is extremely toxic&#xD;
      with grade 4 neutropenia especially for Asian patients. On these grounds, new therapy MESA is&#xD;
      used for Asian patients with ENKTL in order to achieve good efficacy and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response criteria for CR(complete remission)by physical examination,lymph nodes masses and bone marrow test.</measure>
    <time_frame>24 week</time_frame>
    <description>After 6 cycle of MESA treatment,response assessments for CR,PR(partial remission) and NR(no remission) should include appropriate imaging studies(CT,MRI and PET-CT) based on the type of study performed at initial workup, endoscopy with visual inspection, repeat biopsies and measurement of EBV DNA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of survival</measure>
    <time_frame>1 year, 2 years, 3years</time_frame>
    <description>prognosis assessment by rates of survival including PFS(Progression-Free-Survival) and OS(Overall survival)at 1 year,2 years,3 years after induction therapies and follow up therapies.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lymphoma, Extranodal NK-T-Cell</condition>
  <arm_group>
    <arm_group_label>MESA chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4 dexamethasone 20mg/ m2，VD d2，d3，d4，d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MESA chemotherapy</intervention_name>
    <description>Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5</description>
    <arm_group_label>MESA chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MESA</intervention_name>
    <description>Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase</description>
    <arm_group_label>MESA chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological diagnosis is NK/T cell lymphoma；&#xD;
&#xD;
          -  At least one objective evaluation ( measurable ) lesions&#xD;
&#xD;
          -  Age 15 ~ 60 years old, men and women are not limited&#xD;
&#xD;
          -  ECOG(Eastern Cooperative Oncology Group）performance status 0~3，Expected to survive&#xD;
             more than 3 months;&#xD;
&#xD;
          -  Heart, kidney function in the normal range&#xD;
&#xD;
          -  Liver function: transminase&lt; 2 times the normal value&#xD;
&#xD;
          -  pregnancy tests of women childbearing age must be negative; Men and women agree to use&#xD;
             effective contraception during the treatment and the following year&#xD;
&#xD;
          -  Before the test sign the written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The early use of methotrexate or/and L-asparaginase;&#xD;
&#xD;
          -  Pregnant or nursing, psychiatric patients complicated with malignant tumor&#xD;
&#xD;
          -  At the same time the application of other trial drug, drug contraindications exist in&#xD;
             research;&#xD;
&#xD;
          -  Serious infection or metabolic diseases&#xD;
&#xD;
          -  Liver dysfunction, serum direct bilirubin, indirect bilirubin, transaminase 2 times&#xD;
             higher than normal; serum total protein or albumin below normal;&#xD;
&#xD;
          -  Renal insufficiency, creatinine clearance rate was 2 times higher than normal,&#xD;
             especially the creatinine clearance rate is less than 30ml/min;&#xD;
&#xD;
          -  Before entering the group, blood: White blood cell&lt; 3×10E9/L; absolute neutrophil&#xD;
             count&lt;1.5×10E9/L; platelet&lt;100×10E9/L ( bone marrow is not violated ); platelet count&#xD;
             &lt;75×10E9/L ( bone marrow invasion ); hemoglobin&lt;100g/L.&#xD;
&#xD;
          -  In the 6 months before entering the group, patients with uncontrolled or serious&#xD;
             cardiovascular diseases, including myocardial infarction, III-IV class heart failure,&#xD;
             uncontrolled angina or clinically significant pericardial disease, and diabetes and&#xD;
             phlebitis;&#xD;
&#xD;
          -  HIV antibody positive, HBsAg positive after antiviral HBV(hepatitis B virus) DNA titer&#xD;
             in 104copies/ml the following groups. HIV antibody positive, HBsAg+ and DNA titer in&#xD;
             104copies/ml after antiviral HBV therapy&#xD;
&#xD;
          -  Coagulation abnormalities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>RONG LIANG, professor</last_name>
    <phone>86 13384933870</phone>
    <email>rongliang1017@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Zhu, nurse</last_name>
    <phone>96 029 84775203</phone>
    <email>xueyeke@fmmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hemaology, Xi jing Hospital,The Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>rong liang, associate professor</last_name>
      <phone>86 13384933870</phone>
      <email>rongliang1017@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Zhu, nurse</last_name>
      <phone>86 29 775202</phone>
      <email>xueyeke@fmmu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>xie qun chen, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rong Liang, associate professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>August 16, 2013</study_first_submitted>
  <study_first_submitted_qc>August 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2013</study_first_posted>
  <last_update_submitted>December 21, 2013</last_update_submitted>
  <last_update_submitted_qc>December 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Air Force Military Medical University, China</investigator_affiliation>
    <investigator_full_name>Xie-qun Chen</investigator_full_name>
    <investigator_title>Dean of Department of Hematology, Xijing Hosptial</investigator_title>
  </responsible_party>
  <keyword>MESA, chemotherapy,NK/T cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

